Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Citi
Healthtrust
Johnson and Johnson
Cantor Fitzgerald
Cipla
Argus Health
QuintilesIMS
Dow
Federal Trade Commission

Generated: October 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,615,545

« Back to Dashboard

Which drugs does patent 7,615,545 protect, and when does it expire?


Patent 7,615,545 protects SEASONIQUE and LOSEASONIQUE and is included in two NDAs. There have been zero Paragraph IV challenges on LoSeasonique and Seasonique

This patent has thirty-six patent family members in twenty-two countries.

Summary for Patent: 7,615,545

Title:Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Abstract:This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.
Inventor(s): Bell; Robert G. (Palm Harbor, FL), Ben-Maimon; Carole (Merion, PA), Iskold; Beata (Livingston, NJ)
Assignee: Duramed Pharmaceuticals, Inc. (Pomona, NY)
Application Number:11/892,014
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
SEASONIQUE
ethinyl estradiol; levonorgestrel
TABLET;ORAL021840-001May 25, 2006ABRXYesYes► Subscribe► Subscribe PREVENTION OF PREGNANCY
Teva Branded Pharm
LOSEASONIQUE
ethinyl estradiol; levonorgestrel
TABLET;ORAL022262-001Oct 24, 2008ABRXNoNo► Subscribe► Subscribe PREVENTION OF PREGNANCY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,615,545

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,320,969Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
8,338,396Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
8,680,084Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
7,858,605Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,615,545

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1076716► Subscribe
Spain2561491► Subscribe
Spain2428118► Subscribe
European Patent Office2305230► Subscribe
European Patent Office2305229► Subscribe
European Patent Office1453521► Subscribe122015000093Germany► Subscribe
European Patent Office1453521► SubscribeCA 2016 00016Denmark► Subscribe
European Patent Office1453521► Subscribe93156Luxembourg► Subscribe
European Patent Office1453521► Subscribe300814Netherlands► Subscribe
European Patent Office1453521► SubscribeC20160011 00192Estonia► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
McKesson
Fuji
Medtronic
Citi
UBS
Boehringer Ingelheim
Chubb
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot